Loading
When universities license cancer discoveries to companies, the contract would reward companies that price fairly and sell in poor countries, and penalise those that do not, using the royalty rate as the lever.
Technology transfer offices adopt a standard licence for oncology inventions in which the royalty rate steps down when the licensee meets access conditions (registration and tiered pricing in a list of low- and middle-income countries within two years of first approval, non-exclusive licensing to the Medicines Patent Pool for those markets) and steps up if the launch price exceeds a value-based reference. Since a large share of first-in-class cancer drugs originate in academic labs (including the checkpoint inhibitors and CAR-T), universities collectively hold leverage they rarely use. Universities Allied for Essential Medicines has drafted model clauses; the change is to make them the default for cancer.
Shares An oncology patent pool for combination trials across companies, Secrecy and intellectual property block collaboration.
Shares An oncology patent pool for combination trials across companies, Secrecy and intellectual property block collaboration.
Shares An oncology patent pool for combination trials across companies, Secrecy and intellectual property block collaboration.
Shares An oncology patent pool for combination trials across companies, Secrecy and intellectual property block collaboration.
Shares Transferable priority vouchers for first-in-class drugs, with price conditions, Incentives reward me-too drugs and marginal gains.
Shares Secrecy and intellectual property block collaboration, Most of the world has almost no cancer care.
Shares Incentives reward me-too drugs and marginal gains, Most of the world has almost no cancer care.
Shares Transferable priority vouchers for first-in-class drugs, with price conditions, Incentives reward me-too drugs and marginal gains.